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The PK/PD cut-off (PK/PDCO) value of florfenicol for calf pathogens was determined for
long acting formulations (MSD Nuflor® and a bioequivalent generic product). PK/PDCO
is one of the three MICs considered by VetCAST, a sub-committee of the European
Committee on Susceptibility Testing (EUCAST), to establish a Clinical Breakpoint for
interpreting Antimicrobial Susceptibility Testing (AST). A population model was built
by pooling three pharmacokinetic data sets, obtained from 50 richly sampled calves,
receiving one of two formulations (the pioneer product and a generic formulation). A
virtual population of 5,000 florfenicol disposition curves was generated by Monte Carlo
Simulations (MCS) over the 96 h of the assumed duration of action of the formulations.
From this population, the maximum predicted MIC, for which 90% of calves can achieve
some a priori selected critical value for two PK/PD indices, AUC/MIC and T>MIC, was
established. Numerical values were established for two bacterial species of the bovine
respiratory disease (BRD) complex, Pasteurella multocida andMannheimia haemolytica.
It was concluded that the PK/PDCO of florfenicol for both AUC/MIC and T>MIC was
1 mg/L.
Keywords: florfenicol, PK/PD cut-off, Antimicrobial Susceptibility Testing, calves, population pharmacokinetics,
Monte Carlo simulations
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INTRODUCTION
Florfenicol is an antimicrobial drug (AMD) used extensively
to treat Bovine Respiratory Disease (BRD). It’s prudent and
rational use should be based on the results of Antimicrobial
Susceptibility Testing (AST). Clinical breakpoints (CBP) are
the MIC values (units mg/L) used by antimicrobial testing
laboratories to report qualitatively the results of AST as
Susceptible or not. The Veterinary Committee on Antimicrobial
Susceptibility Testing (VetCAST) is a recently established sub-
committee of the European Union Committee on Susceptibility
Testing (EUCAST). EUCAST is the reference committee for
AST in human medicine for the EU and VetCAST operates
within the guidelines and structure of EUCAST. The VetCAST
remit encompasses all aspects of AST of bacterial pathogens
of animal origin and animal bacteria with zoonotic potential.
In the VetCAST approach (Toutain et al., 2017), CBPs are
determined by taking into account at least an epidemiological
cut-off (ECOFF) and a PK/PD cut-off (PK/PDCO). In addition,
a clinical cut-off can also be considered when clinical data are
available to linkMICs to clinical efficacy (Turnidge andMartinez,
2017). PK/PDCO is defined as the highest possible MIC for which
a given percentage of animals in the target population (e.g.,
90%) achieve a pre-defined target value, hereafter named PDT
(pharmacodynamic target) according to European Medicines
Agency (EMA) terminology (European Medicines Agency,
2015). For Histophilus somni (HS), Pasteurella multocida (PM),
and Mannheimia haemolytica (MH), possible florfenicol MICs
for the wild populations ranged from 0.12 to 2 mg/L; MIC90
values were 0.25 mg/L (HS), 0.5 mg/L (PM), and 1 mg/L (MH)
(de Jong et al., 2014).
The Veterinary Antimicrobial Susceptibility Testing (VAST)
sub-committee of the Clinical and Laboratory Standards Institute
(CLSI), hereafter named CLSI/VAST, historically approved CBP
for florfenicol for BRD treatment; selected values were 2, 4,
and 8 mg/L, respectively, for Susceptible (S), Intermediate (I),
or Resistant (R) (Clinical Laboratory Standards Institute, 2018).
To our knowledge, these CBPs were not accompanied by a
CLSI/VAST explanatory document to justify the selected values
for BRD, although this is now the case for all new CLSI/VAST
CBPs. At the time of ascribing these values to florfenicol,
CLSI/VAST did not consider PK/PD relationships in the decision
taking methods for establishing the CBP. In veterinary medicine,
publicly available clinical data on AMD efficacy are generally
scarce or non-existent. For florfenicol, several publications have
described the clinical efficacy of the formulations (MSD Nuflor R©
and its generics) considered in the present paper. Results of
clinical trials for florfenicol were comprehensively analyzed using
a mixed-treatment comparison meta-analysis, which combined
evidence from published trials and published estimates of
comparative efficacy for 12 AMDs registered for use in the
USA (O’Connor et al., 2016). It was concluded that florfenicol
was efficacious, ranking fourth of the 12 AMDs investigated.
VetCAST, having no access to the company files describing the
results of these clinical trials, considers, as do others, that the
pivotal information required to establish a CBP is embedded
in a PK/PD breakpoint (Turnidge and Paterson, 2007). This is
because the PK/PD breakpoint is a hybrid value, incorporating all
three principal components (microbiological, pharmacological,
and clinical) predicting clinical efficacy. Hence, EUCAST
relies on such PK/PD breakpoints to establish CBPs. PK/PD
breakpoints should be clearly distinguished from a PK/PDCO, in
that the latter is derived from PK data only, without any clinical
data input. PK/PDCO is established solely by exploring a range
of possible (not probable) MICs, and the VetCAST methodology
involves computing a series of Probability of Target Attainments
(PTA) from plasma concentration-time profiles. This is also
the procedure adopted by CLSI/VAST under the name PDCO
(Clinical Laboratory Standards Institute, 2018).
VetCAST has re-evaluated the CBP for florfenicol in cattle, in
order to provide a proof of concept of its scientific approach,
which may differ significantly from that of VAST/CLSI in
several respects, including determination of a PK/PDCO. Being
pivotal for the VetCAST approach, a robust estimation of
PK/PDCO requires first the building of a valid population
pharmacokinetic (POP PK) model from individual animal
data collected from differing sources to quantify typical PK
parameters and their between-subject variability (BSV). Simply
retrieving, from literature publications, PK parameters estimated
by others and aggregating them is not used by VetCAST.
Florfenicol and calf pathogens have been selected to illustrate
the VetCAST method of meta-analysis (Li et al., 2015). The
Non-Linear Mixed Effect Model (NLME) is used to handle
unbalanced data (Schoemaker and Cohen, 1996) with one
data set having been analyzed using a mono-compartmental
model (Sidhu et al., 2014), while more recent data sets
have been obtained with a lower limit of quantification
(LLOQ) of the analytical technique, thereby providing an
extended terminal half-life. This is a very common situation in
veterinary medicine, as long-acting (LA) formulations are used
extensively (Toutain and Bousquet-Mélou, 2004).
A further aspect of data analysis, specific to VetCAST, is the
rationale for selecting the most appropriate PK/PD index, either
the time for which plasma concentration remains above the
MIC during the dosage interval (fT>MIC) or the ratio of Area
Under the plasma concentration-time Curve divided by the MIC
(fAUC/MIC), fCmax/MIC being not considered by EUCAST.
The term f indicates that these indices should be computed
in terms of plasma free drug concentrations. For florfenicol in
cattle, the binding to plasma proteins has been reported in several
publications, with very disparate results. At the time of model
building, the most recent protein binding data for florfenicol
were those published by Foster et al. (2016) who concluded
“Florfenicol protein binding was only 5% at the high concentration
and was negligible at the low concentrations, representing a fu of
essentially 1.0.” However, others have reported values ranging
from 10 to∼25% (Adams et al., 1987; Bretzlaff et al., 1987; Lobell
et al., 1994; Sidhu et al., 2014). In light of these data heterogeneity,
it was decided to ignore the extent of drug binding in making the
present computations, as further explained the Discussion.
Florfenicol is often classified as time-dependent in its killing
action and, as for chloramphenicol, T>MIC has been reported as
the appropriate PK/PD index (Martinez et al., 2013). However,
AUC/MIC has also been proposed as the most appropriate
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index predictive of clinical efficacy, especially for PM and MH
(Sidhu et al., 2014). Actually, it has been shown, using a semi-
mechanistic in silico model, that AUC/MIC (and not T>MIC) is
the most appropriate index, when terminal half-life is relatively
long relative to the dosing interval, even for beta-lactam drugs
(Nielsen et al., 2011; Kristoffersson et al., 2016). This is the case
likewise for florfenicol LA formulations. In the VetCAST project,
the best predictive index for florfenicol and its magnitude were
investigated from in silico simulations using a semi-mechanistic
PK/PD model (Nielsen and Friberg, 2013) to replace the classical
in vivo rodent infection model that, for several decades (Craig,
1998; Andes and Craig, 2002), was used to select the best
PK/PD index. VetCAST calculates PDT through an in silico
dose-fractionation approach (Pelligand et al., 2019).
The aim of the present investigation was to build a
population model for florfenicol in cattle, generating by Monte
Carlo simulations (MCS) a large number of plasma florfenicol
disposition curves (n = 5,000). This virtual in silico meta-
population was used to determine the percentages of animals
(PTA) for which a series of possible PDT values would be
attainable with differing possible MICs (actually 0.25, 0.5, 1,
and 2 mg/L).
MATERIALS AND METHODS
Individual calf PK data from three different sources
(A= 10, B= 32, C= 8) were used for the POP PK analysis
(see Supplementary Material, giving raw data). Source A
consisted of 10 calves from a published study (Sidhu et al., 2014).
Source B was a drug company (Norbrook Laboratories Limited);
it comprised 16 calves enrolled in a cross-over bioequivalence
study (MSD Nuflor R© and Norbrook Norfenicol R© formulations)
Norfenicol R© being a FDA and EMA approved generic product
(Anonymous, 2018a). The 32 data sets were provided by 16
sets for each product, so that for this analysis each of these
calves provided two data sets. The third source comprised data
from 8 calves in an unpublished study. All calves were in good
health and all received a subcutaneous florfenicol dose of 40
mg/kg. Table 1 gives details for the three sources of individual
animal data.
Pharmacokinetic data analyses were carried out using
Phoenix R© WinNonlin R© 8.0 (Pharsight Corporation St. Louis,
MO, USA). Data sets obtained from the three sources were
analyzed using a NLME model. A two-compartmental model
was selected, based on the Likelihood Ratio Test (LRT), the
Akaike Information Criterion (AIC), and inspection of different
diagnostic plots (vide infra). For the LRT test, the critical value of
the χ2 distribution considered for a given nominal risk of 0.05,
and a given number of degrees of freedom, was obtained using
the Excel function CHISQ.INV.RT().
The parameterization of the structural two-compartmental
model was of the closed form (Equation 1):




+B× EXP (−Beta× t)
− (A+B)× EXP (−Ka× t) (1)
where t is the time (h) macroconstants, A and B (µg/ml)
are intercepts and Alpha, Beta, and Ka are rate constants
(1/h) associated with the phases of plasma concentration-time
profile. Parameterization was in terms of macroconstants and
rate constants rather than in terms of clearance and volume of
distribution for reasons explained in the Discussion. The five
fixed parameters (described as vector Thetas) were estimated and
reported as typical values (tv) with coefficient of variation as a
measure of precision of the estimate. The random component
that describes biological variability around the structural fixed
parameters i.e., the BSV across individuals was described by an
exponential model of the form (Equation 2):
θ1i = θ1 × Exp (η1i) (2)
where θ1 is the typical population value of theta (A, B, Alpha,
Beta, or Ka), θ1i the value of theta in the ith animal, and η1i
(eta) the deviation associated with the ith animal from the
corresponding theta population value. This exponential model
assumes a log-normal distribution of parameters, i.e., that the
distribution of the etas is normal in the log-domain, with a mean
of 0 and a variance ω2 where:
η ≈ N (0, ω2)









covariance terms between etas have been ignored (diagonal
matrix) to ensure identifiability of the parameters.
The BSVwas reported as coefficient of variation in the original
scale with the following equation that converts the variance terms
(ω2) to a coefficient of variation (CV%).







The residual variability was modeled with an additive and
a multiplicative component. Like other random-effects, the
residual error can be dependent on subject-specific covariate of
the analytical technique used to generate plasma concentration
(Bonate, 2011). Assuming that the residual mainly reflects
variability of the analytical technique, we explored, as a part of
the quality control of the merged data sets, what might be the
precision of the three analytical techniques used to generate the
data i.e., included in the error model was the source of the data as
a covariate. It was concluded that differences were not sufficiently
large to retain this covariate. Therefore, in the final model, a
single residual without covariate was used.
The residual error model without covariate was of the form
(Equation 4):
Y = f (θ ,Time)× (1+ ε1) + ε2 (4)
with ε1 the multiplicative error term having a mean of 0 and a
variance of σ1
ε1 ≈N (0, σ12)
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TABLE 1 | The three data sets considered for florfenicol population pharmacokinetic analysis.








Range of sampling times (h)
after dosing
Products
A Sidhu et al., 2014 10 190 0 0.25 0–80 Nuflor®
B Company 16 240 12 0.05 0–192 Nuflor®
16 240 3 0.05 0–192 Generic (Norfenicol®)
C Unpublished 8 200 7 0.05 0–216 Nuflor®
Total 50 870 22
The 10 calves of the Sidhu’ paper were healthy female Aberdeen Angus calves weighing 145–204 kg and aged 79–131 days. The 16 European stock calves from Company were 7
males and 9 females, aged ∼5–9 months. They were randomly assigned to two treatment groups with 8 animals in each group, in a manner designed to minimize weight differences.
All animals were healthy and physiologically normal. Weights ranged from 136 to 205 kg at selection. The eight unpublished calves were Holstein/Fresian cross-breed and weighed from
108 to 165 kg. Data reported as below the Level of Quantification (<BLQ) obtained after the drug administration was low (2.6%) and were ignored in the present analysis.
and ε2 the common additive error term having a mean of 0 and a
variance noted σ2
ε2 ≈N (0, σ22)
Sigma1 and Sigma2 were estimated by Phoenix and reported as a
CV% for sigma1 and as a STDV for sigma2.
No covariates were included in the final model, as the
computed PK/PDCO is expected to cover all sources of biological
variability across animals. However, in a preliminary analysis,
two covariates were explored, in order to support the merging
of the three data sets (A, B, and C) and the two formulations
(Nuflor R© and generic). There was no major influence of these
covariates (results not shown) and no specific issue linked to the
merging of the data sets.
Parameter estimations, with their associated SE and coefficient
of variation as a measure of the precision of the estimate, were
based on minimizing an objective function value (OFV), using
Laplace engine for the Maximum Likelihood Estimation.
As only 22 florfenicol concentrations were reported as BLQ
(comprising 2.6% of the whole data set), BLQ data were
discounted in the analysis without the risk of introducing bias in
the parameter estimates leading tomodelmis-specification (Byon
et al., 2008). For the two-compartment model, when the BLQ
incidence was <5%, it was shown that omission of the BLQ data
generally did not inflate the bias in the fixed-effect parameters
(Xu et al., 2011).
The shrinkage for the etas was estimated by the equation





where ω is the estimated variability for the population and SD
is the SD of the individual values of the Empirical Bayesian
Estimates (EBE) of η.
Different diagnostic plots were reviewed to determine whether
or not a model was adequate. These included PRED (Population
Predicted Value based on population parameter estimates) and
IPRED (Individual Predicted value based on individual’s ETAs)
vs. the DV (Dependent variable) (with and without a log scale)
Conditional weighted residuals (CWRES) and individual fitting.
The overall adequacy of the 2-compartment PK model was
established by plotting the Visual Predictive Check (VPC) i.e., a
graphical comparison between the observed data and prediction
intervals derived from the simulated data.
Secondary parameters were also computed (terminal half-
lives for the first and second phases of drug disposition and
contribution of the first and second phases to drug absorption).
Monte Carlo simulations (MCS) of the predicted
concentration (IPRED) from the model i.e., simulation of
concentration without the error term from 0 to 96 h post
administration, with a step of 1 h, were used to generate a
meta-population of 5,000 calves. These curves were analyzed
using the Non-Compartmental tool of Phoenix to compute the
areas under the curve and the time above selectedMICs from 0 to
96 h, 96 h being the claimed duration of florfenicol activity after
a single SC administration of Nuflor R© (Anonymous, 2018b). A
PDT of 40% was selected for T>MIC as a default value (Mouton
et al., 2012). These metrics were then analyzed with the statistical
tool of Phoenix to compute the quantiles of interest (90th) to
establish PK/PDCOs.
In human medicine, PK/PD indices and their PDT are
established primarily in rodent models over a fractionated-
dosing interval of 24 h. For florfenicol, such data are not
available. Therefore, in this project, an in silico approach was
used as a surrogate for the dose fractionation trial. Briefly,
PD parameters for florfenicol were first estimated by modeling
killing curves obtained with PM and MH with a semi-
mechanistic model described by others (Nielsen and Friberg,
2013). Then, the selected PD model was solved with average
plasma concentrations predicted by the population model of
the present investigation. This in silico approach established,
retrospectively for the main human AMD classes, all indices
derived using the animal model (Nielsen et al., 2011). It was
concluded that the best index for florfenicol was AUC/MIC. This
component of the project is fully described in a companion paper
(Pelligand et al., 2019).
RESULTS
Figure 1 displays the 50 curves used in the POP PK analysis,
sorted either by sources (n = 3) or by formulations (n = 2).
Figures 2–5 are Goodness-of-fit (GOF) plots supporting the 2-
comparmental structural model; the exponential model for the
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FIGURE 1 | Semi-logarithmic spaghetti plot for 50 calves sorted by sources (left) (Red = A, Gray = B, Blue = C) or by formulation (right) (Black = Nuflor®, Red =
generic). Visual inspection of the plots does not suggest major differences either between the three sources of data or for the two formulations, as seen from the
intermingling of the curves.
FIGURE 2 | Plot of the dependent variable (DV) i.e., plasma florfenicol concentration (µg/ml) vs. population predicted plasma florfenicol concentrations (PRED) (no
random component). The plot illustrates observed vs. fitted values of the model function. Ideally, they should fall close to the line of unity y = x. Arithmetic scale (left)
and logarithmic scale (right). For both arithmetic and logarithmic scales, data were evenly distributed about the line of identity, indicating no major bias in the
population component of the model.
random component; and the additive plus multiplicative model
for the error sub-model used to analyze the data. To evaluate
the adequacy of the developed population model, the VPC
plots are presented in Figure 5, which illustrates the 10th, 50th,
and 90th percentiles of the simulated distribution compared to
the observed values. Typical values of the primary structural
parameters of themodel (thetas), the secondary parameters (half-
life and percentage of the bioavailable dose absorbed during
Alpha and Beta phases), their associated Standard Error (SE)
and the SD of the residual for the basic model are presented
in Table 2.
The coefficient of variation of the multiplicative component
of the residual was 14%. The BSV for the estimated parameters
was ∼20–30% but was 57% for ka, suggesting a homogeneous
exposure between animals for these formulations. This is
consistent with BSV of AUC, as estimated approximately by
others when reporting observedAUCmean and SD (Soback et al.,
1995; Sidhu et al., 2014).
Using the developed population pharmacokinetic model and
estimated parameters, 5,000 curves were generated by Monte
Carlo Simulation (simulated IPREDs taking into account Thetas
and Omega but not Sigma, the residual error) over 96 h with
a step of 1 h; the simulated dosage regimen 40 mg/kg (single
subcutaneous administration). The corresponding AUC from 0
to 96 h and the time for which plasma concentrations remained
above selected MICs are given in Table 3.
Data presented in Table 3 indicates that, for a MIC of
1.0µg/ml, 90% of calves achieved a time above the MIC of at
least 38.70 h i.e., a T>MIC of 40.31% of the duration of the
assumed florfenicol activity of 96 h. Accepting the claim of the
company licensing the pioneer product that the duration of
action of Nuflor R© is 96 h (Anonymous, 2018b) and a default
PDT value of 40% (Mouton et al., 2012), the florfenicol PK/PDCO
for T>MIC was 1.0µg/ml, because, for a higher MIC of
2µg/ml, a T>MIC of 40% was achieved in only 10% of calves.
In accepting AUC/MIC as the appropriate index, the average
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FIGURE 3 | Plot of the dependent variable (DV) i.e., observed plasma florfenicol concentration (µg/ml) vs. individual predicted plasma florfenicol values (IPRED).
Individual prediction was obtained by setting random effects to the “post-hoc” or empirical Bayesian estimate of the random effects for the individual from which the
DV observation was made. Thus, the plots illustrate observed vs. fitted values of the model function. Ideally they should fall close to the line of unity y = x. Arithmetic
scale (left) and logarithmic scale (right). For both the arithmetic and logarithmic scales, data were evenly distributed about the line of identity, indicating no major bias
in the population component of the model.
FIGURE 4 | Plot of CWRES (conditional weighted residuals) against time after
dose (h). Values of CWRES should be approximately N (0, 1) and hence
concentrated between y = −2 and y = +2. Inspection of the figure shows that
data were evenly distributed about zero (see the trends as given by the blue
line) and the red line (with its negative reflection) did not show any fanning,
indicating no bias in the structural model.
concentration over 96 h achieved by at least 90% of calves was
1.18µg/ml. Considering the nearest two-fold MIC value, the
PK/PDCO for this index was also 1µg/ml. This is equivalent to a
classical AUC/MIC of 24 h per day in steady-state conditions, as
traditionally expressed in human medicine (Toutain et al., 2007).
For AUC/MIC values >24 h, the current dosage regimen would
not cover 90% of the population; only 10% of calves would be able
to achieve an AUC/MIC of 48 h (equivalent to an average plasma
concentration of 2µg/ml over the 96 h interval). An average
plasma concentration of 2µg/ml is equal to the VAST/CLSI CBP.
DISCUSSION
FDA guidance indicates that population PK modeling (Food
Drug Administration, 1999) is the only appropriate tool to allow
the meta-analysis of data retrieved from different unbalanced
designs i.e., study designs in which all individuals do not supply
the same amount of information. For the present analysis,
the differences in LLOQ of the analytical technique initially
prevented direct comparison of the data set obtained by Sidhu
et al. (2014) which fitted a one-compartment model (results
not shown) with more recent data obtained with a more
sensitive analytical technique and best fitted to a 2-exponential
model. Population modeling enabled the older, but nevertheless
informative data, to be used to generate a single set of parameters
(with SE) for florfenicol. This further enabled generation byMCS
of a virtual in silico calf population for PK/PDCOs.
Florfenicol disposition in calves has been investigated
following administration by the intravenous route (Varma et al.,
1986); PK parameters were estimated with a plasma clearance
of 2.85 ml/kg/min, a steady-state volume of distribution, Vss,
of 0.75 L/kg, and an elimination t1/2 of 2.86 h. Similar results
were reported for different types of cattle, including dairy cattle
(Soback et al., 1995), dry cows (Bretzlaff et al., 1987), and steers
(Lobell et al., 1994), suggesting no major differences in the
florfenicol disposition profile in different classes of cattle. Hence,
it is likely that the present findings will be representative of and
applicable to differing types of cattle. It is also concluded that a
single CBP for cattle can be proposed for these LA formulations.
In the present analysis, t1/2 values were much longer than after
IV administration, with t1/2 of 16 and 67 h for theAlpha and Beta
phases, respectively. Just as a CBP depends on a specific dosage
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FIGURE 5 | Visual Predictive Check (VPC) obtained with 100 replicates of each animal. The observed quantiles (10, 50, and 90%) were well superimposed on the
corresponding predictive check quantiles over the observed data. Theoretically, ∼20% of the data should be outside the plotted quantiles. The red lines are 10, 50,
and 90% quantiles from the actual observed values. The black lines are the 10, 50, and 90% quantiles from the simulated observations (left). Blue and red shaded
(right) areas correspond to the 95% confidence interval of the three predicted quantiles.
TABLE 2 | Population primary (Thetas) and secondary parameters and random effects (Omega) for florfenicol in calves obtained with a 2-compartment model.
THETAS Estimate Units SE CV% 2.5% CI 97.5% CI
tvKa 0.975 1/h 0.123 12.66 0.733 1.218
tvA 5.05 µg/ml 0.2368 4.69 4.59 5.52
tvAlpha 0.0442 1/h 0.0041 9.35 0.0361 0.0523
tvB 0.781 µg/ml 0.243 31.13 0.304 1.258
tvBeta 0.0104 1/h 0.0019 18.31 0.0067 0.0141
tvC1MultStdev 0.1397 0.014 10.37 0.111 0.168
tvC1MultStdev 13.970 %
Covariate analytical method source C −0.579 Scalar 0.195 −33.73 −0.963 −0.196
Covariate analytical method source B 0.151 Scalar 0.163 107.85 −0.169 0.472
stdev0 0.0152 µg/ml 0.0112 73.64 −0.0068 0.0371
OMEGA Variance SE BSV (CV%) Shrinkage
nKa 0.279 0.076 56.69 0.051
nAlpha 0.033 0.012 18.23 0.148
nB 0.036 0.051 19.11 0.544
nBeta 0.103 0.040 32.97 0.145
nA 0.080 0.024 28.92 0.050
Secondary parameters Estimate Units SE CV% 2.5% CI 97.5% CI
Half-life Alpha 15.7 h 1.46 9.35 12.8 18.5
Half-life Beta (t1/2) 66.7 h 12.21 18.31 42.7 90.6
AUC (0-infinity) 183.4 µg*h/ml 3.41 1.86 176.1 190.1
Absorption first phase 0.603 Fraction 0.058 9.64 0.489 0.717
Absorption second phase 0.397 Fraction 0.058 14.66 0.283 0.511
For interpretation of parameters, see Equations (1) (Thetas) and (2) (Omega). AUC was obtained by integrating Equation (1) with estimated tv of thetas parameters. The disposition of
florfenicol for the investigated formulations obeys a flip-flop pattern (Discussion) and fraction absorbed during the first vs. the second phase was estimated by computing partial areas
associated with the alpha phase (A/Alpha) and the beta phase (B/Beta). Shrinkage was from 0 to 1.
regimen (Heil and Johnson, 2016), the computed PK/PDCO
(in the present analysis) is specific for these LA formulations,
administered SC as a single dose of 40 mg/kg with an assumed
duration of effect of 4 days. It cannot be assumed that the findings
apply to any other dosage regimens and/or other formulations
and/or other routes of administration. For example, for another
LA florfenicol formulation, it has been shown that the mean
differences between a SC and intramuscular (IM) administration
were as high as 35 and 63%, respectively, for AUC and Cmax,
the IM administration route thus leading to higher florfenicol
exposure than subcutaneous dosing (Lacroix et al., 2011).This
is typical for veterinary medicine, in which many modalities of
AMD administration exist, rendering a universal and robust CBP
difficult to propose (Toutain et al., 2017).
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The very long terminal t1/2 is explained by flip-flop PK, with
the Alpha phase corresponding to a first process of relatively
slow absorption and the terminal Beta phase corresponding to
a very slow absorption process. It is concluded that the respective
contributions of the Alpha and Beta phases to the total AUC
were∼60% of the bioavailable florfenicol fraction absorbed in the
Alpha phase and 40% in the Beta phase. This second phase is not
well-characterized in several publications having a rather high
analytical method LLOQ. Nevertheless, the population model
allows incorporation of all data in calculating the PK/PDCO.
The flip-flop PK profile of the investigated florfenicol
formulation is also the basis for choosing to parameterize
the model in terms of macroconstants, rather than in terms
of clearance and volume of distribution, as is usually the
case in population modeling. Indeed, the aim was to simulate
5,000 curves and, whatever the parameterization, the plasma
concentration vs. time curves will be the same. From a
mechanistic point of view, however, it is important to explore,
when estimating PK/PDCO, the influence (or not) of the two
major covariates involved, namely a possible “formulation” effect
(here Nuflor R© vs. generic) and a possible “source” effect (here
three sources). For both covariates, it is the relative bioavailability
that may differ rather than clearance, which is not determinable
when only extravascular data are available. To explore the
influence of the covariates in question, the Alpha and Beta slopes
are the two parameters to be estimated as primary rather than
secondary parameters—hence our parameterization.
The final objective of this population pharmacokinetic
analysis was to determine a possible PK/PDCO for florfenicol,
this being the pivotal parameter considered by VetCAST in
the decision making process for establishing a CBP. PK/PDCO
provides insight into the overall PK variability across the targeted
populations, because of the relationship between drug exposure
and efficacy. This relationship is expressed through PK/PD
indices (AUC/MIC ratio or T>MIC) which should achieve
critical values to predict clinical efficacy. The magnitude of a PK-
PD index providing an appropriate level of predicted response is
the PDT (European Medicines Agency, 2015).
As explained in Materials and Methods, no dose-fractionation
has been conducted in rodents to determine the best PK/PD
index predictive of florfenicol efficacy and in this project an in
silico approach was used as a surrogate for a dose fractionation
trial. It was concluded that the best index was AUC/MIC.
This is consistent with the opinion that AUC/MIC is always
the most relevant index, when the terminal half-life is long
(Nielsen et al., 2011). In addition, it was established that the
PDT should be ∼24 h per day, indicating that, to achieve
an in silico bacteriological eradication, the average florfenicol
concentration over the 4 days should be equal to the MIC
[see Toutain et al. (2007) for explanation of the relationship
between PDT expressed in h vs. as a scaling factor]. This is
slightly lower than the bactericidal PDT reported from the killing
action of florfenicol against MH and PM from modeling of the
time-kill data after 24 h exposure of florfenicol to a constant
concentration (Illambas et al., 2013).
From the 5,000 curves generated by MCS, the average plasma
concentration was estimated to be 1.2µg/ml (Table 2) and
1µg/ml is the PK/PDCO value for the AUC/MIC index. An
identical PK/PDCO of 1µg/ml has been derived for florfenicol
in pigs, but for a dose of 30 mg/kg (Lei et al., 2018). Florfenicol
has been classified as a bacteriostatic drug. It can therefore be
argued that T>MIC is also valuable in respect of detection of
resistance. However, as quoted by others (Dudley and Ambrose,
2000), the dual aim of achieving a single breakpoint to predict
both clinical outcome and avoidance of resistance is likely to fail
in many circumstances and constitutes a source of confusion.
Nevertheless, the PK/PDCO for T>MICwas computed, assuming
that the current dosage regimen should ensure a T>MIC for
∼40% of the duration of treatment in 90% of animals: a critical
MIC of 1.0µg/ml was obtained, a value identical with the critical
value for the AUC/MIC index. In the present data analysis a PTA
of 90% was used to compute the PK/PDCO, a quantile that is
routinely used for PTA analysis (Turnidge and Paterson, 2007). It
should be noted that the quantile 90% is related to the concept of
prediction interval and not to the concept of confidence interval.
Moreover, the PK/PDCO as applied by VetCAST is not equivalent
to the EUCAST PK/PD breakpoint, as the latter takes account
additionally of clinical data (Mouton et al., 2012).
In this investigation florfenicol binding to plasma protein
was discounted; as discussed in the Introduction, very disparate
figures have been reported in cattle, ranging from no binding
to binding of 10 to ∼25%. Recently, binding was reported with
a wide BSV: values in a cohort of 20 calves ranged from 1.88
to 57.5% in 7 day old calves and from 16.8 to 27.8% in 46
day old calves, both at a florfenicol concentration of 1 mg/L
(Mzyk et al., 2018). In addressing these differences, we considered
that, for the present study, it was appropriate to consider that
plasma protein binding of florfenicol was negligible, as suggested
by Foster et al. (2016). This approach will render easier any
possible future update of computed PK/PDCO for the selected
PK/PD index (i.e., AUC/MIC), because the extent of binding is
simply a scaling factor for this PK/PD index. Equally important,
it seems probable that the variability reported by Mzyk et al.
(2018) is not simply associated with some technical issue, but
rather actually reflects a true BSV. At present, to the best
of our knowledge, this variability is not factored into models
used, in veterinary medicine, to compute the PTA using MCS.
It is the average value which is adopted. If a wide BSV for
protein binding was, in due course, confirmed for florfenicol
in cattle, it would be necessary not only to scale our results
but to re-run the population model to include this source
of variability. To summarize, what has been determined in
this paper, as a PK/PDCO, is the simplest hypothesis of no
plasma protein binding (and thus no variability for this factor)
for florfenicol.
In conclusion, any CBP is both dose- and exposure-
dependent. In human medicine most AMDs are administered
by the oral route and CBPs have a generic value for oral
formulations that are relatively similar in terms of the internal
exposure they provide. This is unfortunately not the case for
veterinary medicine, where CBPs can also be “formulation-
dependent.” The formulations, Nuflor R© from MSD and its
generics, evaluated in this study were all administered by the
subcutaneous route, these being the most extensively used
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TABLE 3 | AUC (0–96 h), average concentration (µg/ml), and Time (h) above possible MICs ranging from 0.25 to 2µg/ml for selected quantiles and corresponding value
of the T>MIC in % of 96 h, the claimed duration of action of Nuflor®.
MIC (µg/ml) Quantiles%
99 95 90 75 50 25 10 5 1
Time above (h) MIC 0.25 74.29 85.54 91.89 95.88 95.92 95.94 95.95 95.96 279.1
Time above (h) MIC 0.5 50.96 58.37 62.46 70.44 80.19 91.1 95.86 95.89 119.88
Time above (h) MIC 1 30.42 35.59 38.7 43.94 50.64 57.72 65.18 70.15 80.21
Time above (h) MIC 2 11.81 16.35 18.9 22.87 28 33.45 39.29 42.63 49.62
Time above MIC (% of 96 h) 0.25 77.38 89.1 95.72 99.87 99.92 99.94 99.95 99.96 290.73
Time above MIC (% of 96 h) 0.5 53.08 60.8 65.06 73.37 83.53 94.9 99.85 99.89 124.87
Time above MIC (% of 96 h) 1 31.69 37.07 40.31 45.77 52.75 60.12 67.89 73.07 83.55
Time above MIC (% of 96 h) 2 12.3 17.03 19.68 23.82 29.17 34.85 40.93 44.41 51.69
AUC (0–96 h) µg*h/ml 88.5 103.4 113.1 130.5 153.6 181 211.1 232.5 291
Average concentration (µg/ml) over 96 h µg/ml 0.92 1.08 1.18 1.36 1.6 1.89 2.2 2.42 3.03
Time above MICs (from 0.25 to 2µg/ml) was computed from the 5,000 curves generated by MCS using the population model. Bold values indicates values for the selected PK/PD
cut-off.
formulations and route of administration for florfenicol in cattle.
However, other florfenicol formulations and other routes of
administration are used in cattle, so that VetCAST CBP is
not guaranteed to be applicable to other formulations and/or
other routes of administration. These issues are discussed in the
VetCAST position paper (Toutain et al., 2017). Finally from a
pooled raw data analysis, using a NLME and MCS for florfenicol,
a PK/PDCO of 1 mg/L is proposed for the extensively used LA
florfenicol formulations investigated.
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